Valuation: Opus Genetics, Inc.

Market Cap 27Cr 24Cr 22Cr 20Cr 38Cr 2.6TCr 39Cr 260.41Cr 102.28Cr 1.27TCr 101.39Cr 99Cr 4.38TCr P/E 2026 *
-3.05x
P/E 2027 * -4.31x
Enterprise Value 27Cr 24Cr 22Cr 20Cr 38Cr 2.6TCr 39Cr 260.41Cr 102.28Cr 1.27TCr 101.39Cr 99Cr 4.38TCr EV / Sales 2026 *
17.8x
EV / Sales 2027 * 18.2x
Free-Float
88.94%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Opus Genetics, Inc.

1 day-0.30%
1 week-16.58%
Current month-20.44%
1 month-19.66%
3 months-43.13%
6 months+55.71%
Current year+62.69%
1 week 3.18
Extreme 3.1813
3.91
1 month 3.18
Extreme 3.1813
4.39
Current year 1.88
Extreme 1.88
5.81
1 year 1.04
Extreme 1.04
5.81
3 years 0.65
Extreme 0.65
5.81
5 years 0.65
Extreme 0.65
6.6
10 years 0.65
Extreme 0.65
13.81
Manager TitleAgeSince
Chief Executive Officer 42 01/11/2023
Director of Finance/CFO 52 02/09/2025
President 60 22/10/2024
Director TitleAgeSince
Director/Board Member 77 01/11/2020
Chairman 56 01/12/2019
Director/Board Member 59 01/11/2020
Date Insider Type Main position Quantity % Market Cap.
18/05/26
The Foundation Fighting Blindness, Inc.
SellCompany -17,00,000 2.0886%
23/04/26 Sell

Chief Operating Officer

4,697 0.0066%
23/04/26 Sell

Chairperson

7,470 0.0105%
Change 5-day change 1-year change 3-year change Capi.($)
-0.30%-16.58%+189.38%-19.46% 27Cr
+0.85%-0.80%+52.79%+161.33% 1,05100Cr
+1.23%-1.53%+54.58%+59.08% 61TCr
+0.04%+2.58%+34.47%+86.33% 45TCr
+0.78%-0.71%+30.04%+24.61% 33TCr
+1.41%+0.58%+33.92%+47.20% 28TCr
-0.27%-1.87%+22.13%+23.47% 26TCr
-1.76%+2.37%-22.19%-38.45% 22TCr
-1.42%+0.80%+24.27%+57.50% 20TCr
-1.48%+3.43%+24.08%+71.67% 17TCr
Average -0.09%-1.17%+44.35%+47.33% 35.75TCr
Weighted average by Cap. +0.37%+0.02%+37.34%+80.23%

Financials

2026 *2027 *
Net sales 1.52Cr 1.33Cr 1.22Cr 1.13Cr 2.13Cr 146.16Cr 2.17Cr 15Cr 5.75Cr 72Cr 5.7Cr 5.58Cr 246.46Cr 1.48Cr 1.3Cr 1.2Cr 1.1Cr 2.08Cr 142.79Cr 2.12Cr 14Cr 5.62Cr 70Cr 5.57Cr 5.45Cr 240.78Cr
Net income -9.45Cr -8.26Cr -7.62Cr -7.02Cr -13Cr -909.76Cr -14Cr -91Cr -36Cr -445.41Cr -35Cr -35Cr -1.53TCr -6.78Cr -5.93Cr -5.47Cr -5.04Cr -9.5Cr -652.48Cr -9.71Cr -65Cr -26Cr -319.45Cr -25Cr -25Cr -1.1TCr
Net Debt - -
Logo Opus Genetics, Inc.
Opus Genetics, Inc. is a clinical-stage ophthalmic biotechnology company. The Company is engaged in developing gene therapies for the treatment of inherited retinal diseases (IRDs) and other types of therapies for additional ophthalmic disorders. The Company’s pipeline includes adeno-associated virus (AAV)-based investigational gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA) and retinitis pigmentosa. Its pipeline also includes OPGx-BEST1 investigational gene therapy, designed to address mutations in the BEST1 gene, which is associated with retinal degeneration. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist being investigated to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 being investigated to slow the progression of non-proliferative diabetic retinopathy.
Employees
28
Date Price Change Volume
17/26/17 $3.270 -0.30% 5,07,528
16/26/16 $3.280 -5.75% 11,10,044
15/26/15 $3.480 -2.25% 6,67,327
14/26/14 $3.560 -6.56% 9,71,328
13/26/13 $3.810 -2.81% 8,95,050
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
18
Last Close Price
3.270USD
Average target price
10.56USD
Spread / Average Target
+222.80%

Quarterly revenue - Rate of surprise